Chang Kathleen, Wan Jovian, Yoon Song-Eun, Wong Sky, Yi Kyuho
Aesthetics, Harmony Aesthetic Clinic, Adelaide, AUS.
Research, Medical Research Inc., Wonju, KOR.
Cureus. 2024 Dec 9;16(12):e75426. doi: 10.7759/cureus.75426. eCollection 2024 Dec.
To date, no investigations have been published regarding the concentration, dose, and technique for a mucosal spray application of botulinum toxin A (BTA) to alleviate hypersecretory symptoms of rhinitis in humans. It is a promising option for reducing common symptoms of seasonal allergic rhinitis (AR) and idiopathic non-AR. It is safer and less painful than intranasal injections, with high reported satisfaction in reducing clinical symptoms.
Seventeen patients with idiopathic rhinitis who presented to a private clinic in Australia were given 25 units of BTA (Letybo®, Hugel, South Korea) at a concentration of 50 U/mL in normal saline in each nostril via a mucosal atomizer device. At 4 and 12 weeks, a survey of symptom relief, satisfaction with treatment, and willingness to get a repeat treatment was collected.
Patients were otherwise healthy, and the mean age was 40.1 ± 19.4 years. The majority (15 of 17) of subjects at 4 and 12 weeks reported significant symptom relief and high satisfaction, and were willing to get a repeat treatment. No adverse effects were reported.
Topical application of BTA on the nasal mucosa can be considered an effective therapeutic option in patients with persistent AR and idiopathic rhinitis. In comparison with injection techniques, BTA mucosal spray is effective at reducing persistent symptoms while minimizing the risk of pain and inadvertent systemic injection, and is able to promote contact with a wider mucosal area. Furthermore, it is easy to perform and is more tolerable for the patient. The authors present recommended concentrations, doses, and techniques.
迄今为止，尚未有关于将A型肉毒杆菌毒素（BTA）经黏膜喷雾给药以缓解人类鼻炎分泌亢进症状的浓度、剂量和技术的研究发表。这是减轻季节性变应性鼻炎（AR）和特发性非AR常见症状的一个有前景的选择。它比鼻内注射更安全、疼痛更少，据报道在减轻临床症状方面满意度较高。
17例到澳大利亚一家私人诊所就诊的特发性鼻炎患者，通过黏膜雾化装置，在每个鼻孔给予浓度为50 U/mL的BTA（Letybo®，韩国休格公司）25单位，用生理盐水配制。在第4周和第12周，收集症状缓解情况、治疗满意度以及再次接受治疗意愿的调查。
患者其他方面健康，平均年龄为40.1±19.4岁。多数（17例中的15例）受试者在第4周和第12周报告症状明显缓解且满意度高，并愿意再次接受治疗。未报告不良反应。
BTA局部应用于鼻黏膜可被视为持续性AR和特发性鼻炎患者的一种有效治疗选择。与注射技术相比，BTA黏膜喷雾在减轻持续性症状的同时，能将疼痛和意外全身注射的风险降至最低，并能促进与更广泛黏膜区域的接触。此外，其操作简便，患者耐受性更好。作者给出了推荐的浓度、剂量和技术。
